EUVIMEDEUVIMED entdecken
Open Access

Inhibition of MAFB and PI3K/AKT Signaling for Hereditary FSGS with Multicentric Carpotarsal Osteolysis

Toshiaki Usui iD, Shun Ishibashi, Ryojiro Tanaka iD, Naoki Morito iD, Michito Hamada iD, Natalia Gogoleva iD, Baoshuo Ning, Eugenia Kumaga iD, Mayuko Oki, Yuki Tsunakawa, Yuka Murakami, Shunya Sadaki und 16 weitere

Journal of the American Society of Nephrology · 2026

DOI: 10.1681/asn.0000001060 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Society of Nephrology, 2026. Verfasst von Toshiaki Usui und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan. Hauptthemen laut MEDLINE: MafB Transcription Factor, Proto-Oncogene Proteins c-akt, Phosphatidylinositol 3-Kinases, Osteolysis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Kaken Pharmaceutical, Sophie's Neighborhood, JST-Mirai Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Key Points Multicentric carpotarsal osteolysis, a rare disorder, causes progressive osteolysis and kidney failure because of v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog B (MAFB) gene mutations. A genome-edited mouse model carrying the multicentric carpotarsal osteolysis mutation was used to obtain a deeper understanding of this rare disease. Targeting MAFB/IGF-1/PI3K/AKT signaling may provide new treatments for multicentric carpotarsal osteolysis–related nephropathy.

Background

Multicentric carpotarsal osteolysis (MCTO) is a rare condition characterized by progressive osteolysis and often kidney failure. It is caused by autosomal dominant mutations in the transcription factor v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog B ( MAFB ).

Methods

Given the absence of efficacious therapeutic interventions for MCTO and the obscurity of its pathophysiologic mechanisms, we used mice with the MCTO mutation ( Mafb MCTO/MCTO mice) to explore the role of MAFB.

Results

Mafb MCTO/MCTO mice displayed FSGS, mirroring the manifestations seen in patients with MCTO. These mice showed that the MCTO mutation leads to the accumulation of MAFB protein. Heterozygous Mafb MCTO/− mice, generated by crossbreeding to reduce MAFB levels, neither exhibited albuminuria nor showed any histologic abnormalities in the kidney, suggesting that excess MAFB was detrimental. We subsequently conducted RNA-seq on the glomeruli from Mafb MCTO/MCTO mice and detected pronounced upregulation of the phosphoinositide 3-kinase (PI3K)/AKT signaling pathway through IGF-1. Given that receptor tyrosine kinases activate PI3K/AKT, we treated Mafb MCTO/MCTO mice with the inhibitor imatinib. This led to a significant decline in urinary albumin levels compared with the control group.

Conclusions

Our findings demonstrate that the MCTO mutation resulted in MAFB protein accumulation and led to the development of FSGS in mice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MafB Transcription FactorProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesOsteolysisGlomerulosclerosis, Focal SegmentalAnimalsSignal TransductionMiceDisease Models, AnimalMutationMaleFemale

Stichwörter der Autor:innen

genetic renal diseasepodocytetranscription factors

Substanzen

MafB Transcription FactorProto-Oncogene Proteins c-aktMafb protein, mousePhosphatidylinositol 3-Kinases

Autor:innen und Institutionen

  • Department of Nephrology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
  • Doctoral Program in Medical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan.
  • Department of Nephrology, Hyogo Prefectural Kobe Children's Hospital, Kobe, Japan.
  • Department of Anatomy and Embryology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
  • Center for Medical Sciences, Ibaraki Prefectural University of Health Sciences, Ami, Japan.
  • Department of Endocrinology and Metabolism, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.

ORCID-Profile: Toshiaki Usui, Ryojiro Tanaka, Naoki Morito, Michito Hamada, Natalia Gogoleva, Eugenia Kumaga, Sayaka Fuseya, Maho Kanai, Teppei Nishino, Yoshinori Sato, Kei Gochi, Akihiro Kuno, Eiji Warabi, Takashi Kudo, Masafumi Muratani, Michael A Levine, Kunihiro Yamagata, Satoru Takahashi

Förderung

  • Kaken Pharmaceutical
  • Sophie's Neighborhood
  • JST-Mirai Program
  • Bayer Academic Support

Zitieren

APA

Usui, T., Ishibashi, S., Tanaka, R., Morito, N., Hamada, M., Gogoleva, N., Ning, B., Kumaga, E., Oki, M., Tsunakawa, Y., Murakami, Y., Sadaki, S., Fuseya, S., Kanai, M., Nishino, T., Inoue, Y., Sato, Y., Gochi, K., Shinohara, M., …, & Takahashi, S. (2026). Inhibition of MAFB and PI3K/AKT Signaling for Hereditary FSGS with Multicentric Carpotarsal Osteolysis. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.0000001060

Vancouver

Usui T, Ishibashi S, Tanaka R, Morito N, Hamada M, Gogoleva N, et al. Inhibition of MAFB and PI3K/AKT Signaling for Hereditary FSGS with Multicentric Carpotarsal Osteolysis. Journal of the American Society of Nephrology. 2026. doi:10.1681/asn.0000001060

BibTeX
@article{Usui2026,
  author = {Usui, Toshiaki and Ishibashi, Shun and Tanaka, Ryojiro and Morito, Naoki and Hamada, Michito and Gogoleva, Natalia and Ning, Baoshuo and Kumaga, Eugenia and Oki, Mayuko and Tsunakawa, Yuki and Murakami, Yuka and Sadaki, Shunya and Fuseya, Sayaka and Kanai, Maho and Nishino, Teppei and Inoue, Yuri and Sato, Yoshinori and Gochi, Kei and Shinohara, Masahiro and Kuno, Akihiro and Jeon, Hyojung and Warabi, Eiji and Kudo, Takashi and Mizuno, Seiya and Muratani, Masafumi and Levine, Michael A and Yamagata, Kunihiro and Takahashi, Satoru},
  title = {Inhibition of MAFB and PI3K/AKT Signaling for Hereditary FSGS with Multicentric Carpotarsal Osteolysis},
  journal = {Journal of the American Society of Nephrology},
  year = {2026},
  doi = {10.1681/asn.0000001060}
}
Kostenlos starten →